Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

BACKGROUND: Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter, randomized, phase 3 study to compare the efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jie, Pan, Yueyin, Shi, Qin, Zhang, Guojun, Jiang, Liyan, Dong, Xiaorong, Gu, Kangsheng, Wang, Huijuan, Zhang, Xiaochun, Yang, Nong, Li, Yuping, Xiong, Jianping, Yi, Tienan, Peng, Min, Song, Yong, Fan, Yun, Cui, Jiuwei, Chen, Gongyan, Tan, Wei, Zang, Aimin, Guo, Qisen, Zhao, Guangqiang, Wang, Ziping, He, Jianxing, Yao, Wenxiu, Wu, Xiaohong, Chen, Kai, Hu, Xiaohua, Hu, Chunhong, Yue, Lu, Jiang, Da, Wang, Guangfa, Liu, Junfeng, Yu, Guohua, Li, Junling, Bai, Jianling, Xie, Wenmin, Zhao, Weihong, Wu, Lihong, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753311/
https://www.ncbi.nlm.nih.gov/pubmed/34699693
http://dx.doi.org/10.1002/cac2.12225

Ejemplares similares

Ejemplares similares